Please login to the form below

Not currently logged in

New cancer meds and drug extensions top CHMP recommendations

EU flagDrugs for rare disease, oncology and diabetes top regulator’s endorsements

Gilead's Harvoni gains NICE yes - but won't face funding delay

gilead-harvoni-ledipasvir-sofosbuvirUnlike the company's Sovaldi, which won’t be paid for until the summer

J&J sells Cordis unit to Cardinal Health for $1.94bn

Johnson and Johnson logoMarks J&J’s exit from the cardiovascular stent market

Complaints about UK medical advertising drop

mhra logoAnd this year the MHRA will be vetting adverts to promote a ‘right first time’ approach

GSK public-private partnership CTTV names director

Centre for Therapeutic Target Validation launched last year

Novartis and GSK complete oncology and vaccines swap

Follows Swiss company's decision to divest its BRAF and MEK inhibitors to Array BioPharma

Amgen's Kyprolis tops Velcade in myeloma trial

Amgen flagAmgen hoping to topple Takeda’s $2bn a year drug

Sanofi’s Lantus follow-up nears European approval

Sanofi receptionCHMP backing for Toujeo follows hot on the heels of its US approval by the FDA

darwins medicineDoes 'trust leadership' feature in your strategy?

Pharma companies wanting to be more patient-focused will need to develop their people skills

Latest appointments

Featured jobs

Subscribe to our email news alerts


Add my company
Liberation Unlimited

'Progressive', 'cutting edge' – words used to describe Liberation Unlimited. We believe looking forward is essential to delivering successful and...

Latest intelligence

Growing influence of pharmacists in the sale of Rx and OTC medicines
Find out how the changes within pharmacy have affected their influence over the sales of RX and OTC medicines in this whitepaper....
Drivers of 2014′s Soaring Drug Approvals
The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...
Russian innovation at the crossroads
Despite improvements, investors face rising risks...